Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11 Vector   (CAT#: GTVCR-WQ67MR)

This product GTVCR-WQ67MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting ALB&IL6R. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Humanized
RefSeq NM_000477.7; NM_002190.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 213; 3570
UniProt ID P02768; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11 Vector (GTVCR-WQ67MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ619MR IVTScrip™ pT7-VEE-mRNA-Anti-F11, BAY 1213790 Vector Vector BAY 1213790
GTVCR-WQ522MR IVTScrip™ pSP6-VEE-mRNA-Anti-TFPI, Anti-TFPI Vector Vector Anti-TFPI
GTVCR-WQ2410MR IVTScrip™ pSP6-VEE-mRNA-Anti-IFNA1, RhuMAB IFNalpha Vector Vector RhuMAB IFNalpha
GTVCR-WQ1607MR IVTScrip™ pT7-VEE-mRNA-Anti-VSIR, JNJ-61610588 Vector Vector JNJ-61610588
GTVCR-WQ1686MR IVTScrip™ pSP6-VEE-mRNA-Anti-FN1, L19-IL-2 Vector Vector L19-IL-2
GTVCR-WQ1568MR IVTScrip™ pT7-VEE-mRNA-Anti-PDCD1, INCMGA-00012 Vector Vector INCMGA-00012
GTVCR-WQ524MR IVTScrip™ pT7-VEE-mRNA-Anti-FASLG, APG-101 Vector Vector APG-101
GTVCR-WQ1242MR IVTScrip™ pSP6-VEE-mRNA-Anti-MS4A1, GA101 Vector Vector GA101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW